Remodelin

Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model[1][2][3][4].

Product Specifications

CAS Number

[949912-58-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Acetyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Remodelin.html

Purity

99.84

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1

Molecular Formula

C15H14N4S

Molecular Weight

282.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Larrieu D, et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014 May 2;344 (6183) :527-32.|[2]Ma N, et.al. Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication. Int J Mol Sci. 2022 Jun 12;23 (12) :6573. |[3]Balmus G, et.al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun. 2018 Apr 27;9 (1) :1700. |[4]Zhang X, et.al. N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition. Oxid Med Cell Longev. 2019 Jul 1;2019:7561879.